Navigation Links
Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China

BEIJING, June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical products in China, said today that it has become the exclusive distributor in North China of a sophisticated anesthesia product manufactured by Penlon, a UK firm specializing in anesthesia and breathing equipment for 60 years.

Dehaier Medical Systems has been designated by Guangdong Biolight Meditech Co., Ltd., (Penlon Ltd.'s exclusive distributor in China) as the exclusive distributor of Penlon's Prima SP Anaesthesia System (SP101 and SP102) in North China. North China includes six provinces and the cities of Beijing, Tianjin, Hebei, Shandong, Shanxi and Inner Mongolia. The authorization period runs through 2012.

The Prima SP Anesthesia System provides sophistication in a flexible, easy to use package, designed to meet all anesthesia requirements:

    -- Advanced easy to use features for maximum patient safety
    -- Comprehensive choice of layout through modular open architecture
    -- Ultra low flow anesthesia
    -- 'Life-Care' or optional 'Life-Care Plus' Warranty and Customer Care

Mr. Ping Chen, Dehaier's Chief Executive Officer, said, "We are continuing to build our line of products and expand our offerings to our customers including hospitals, clinics and government health bureaus. Becoming the exclusive distributor of Penlon in North China is an important opportunity for our company that provides us with access to the $70 million per year market segment for foreign-made anesthesia systems, thus doubling Dehaier's addressable market for anesthesia systems."

Dehaier is currently a provider of Chinese-made anesthesia systems, a market the company estimates is also around $70 million per year.

About Penlon Ltd.

Penlon is a world-class company, established in Oxford, UK in 1943. It exports to over ninety countries worldwide, including China and Japan, and in the USA through their wholly-owned subsidiary based in Minnetonka, Minnesota. Penlon has a broad range of innovative market leading products and systems with well-established brand names, such as anesthesia, intubation, oxygen therapy and suction, and medical gas pipelines. The company is headquartered and has assembly and component manufacturing facilities in Abingdon in Oxfordshire, UK. Website:

About Dehaier Medical Systems Ltd.

Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Timesco (UK), ResMed (Australia), Welch Allyn (USA), HEYER (Germany), Penlon (U.K.) and JMS (Japan). Dehaier's technology is based on two patents, five pending patents and proprietary technology. More information may be found at .

Information for investors, including an investment profile about Dehaier is available at . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at .

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Investor contact:
     Hawk Associates
     Julie Marshall or Frank Hawkins
     Tel:   +1-305-451-1888

SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
2. Huiheng Medical, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
3. China Sky One Medical Receives GMP Re-Certification
4. Concord Medical Announces First Quarter 2010 Financial Results
5. Mount Sinai Medical Center Drives Genomic Research Collaboration with Isilon Scale-out NAS
6. SPO Medical Announces Innovative Wellness Bracelet
7. Ziehm Imaging and Pie Medical Imaging Announce Cooperation
8. Biomedical Structures Receives Growth Capital from Ampersand Ventures to Fund Ongoing Expansion
9. Highly Regarded Medical Writer Joins Avant Healthcare Marketing Team
10. Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences
11. Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
(Date:11/25/2015)... November 25, 2015 2 nouvelles études ... les différences entre les souches bactériennes retrouvées dans ... des êtres humains . Ces recherches  ouvrent une ... la prise en charge efficace de l,un des ... les chats .    --> 2 nouvelles ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
Breaking Biology Technology:
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
Breaking Biology News(10 mins):